pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
Sep 17, 26
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
Sep 17, 26
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
Sep 17, 26
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
Sep 17, 26
STAT+: A biotech hedge fund births a new immunology company
stat
Sep 17, 26
Roche, Dualitas team up to find bispecific drugs for immune diseases
biopharma dive
Sep 17, 26
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
Sep 17, 26
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
Sep 17, 26
STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
stat
Sep 16, 26
Sling banks $123M for an experimental thyroid eye disease pill
biopharma dive
Sep 16, 26
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
Sep 16, 26
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
Sep 15, 26
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
Sep 15, 26
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Sep 15, 26
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
Sep 15, 26
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
biospace
Sep 15, 26
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
fiercebiotech
Sep 15, 26
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
Sep 14, 26
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
Sep 14, 26
BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer
endpoints
Sep 14, 26
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
Sep 14, 26
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
Sep 14, 26
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
Sep 14, 26
Cyclic peptides open new drug frontiers, if manufacturing can keep up
biospace
Sep 14, 26
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 13, 26
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
Sep 11, 26
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
Sep 11, 26
Novartis drags peers down with triple asset stumble
biospace
Sep 11, 26
Novartis drags peers down with triple asset failure
biospace
← prev
page 12 of 27
next →